Asia Pacific Plasmapheresis Machines Market

Market Overview

A plasmapheresis machine is a device that uses plasmapheresis to collect small amounts of blood at a time. Plasmapheresis is a process that includes separating blood into plasma and cells before returning the cells to circulation. In the therapy of autoimmune illnesses, it is done exactly to remove antibodies. Pheresis, also known as apheresis, is a procedure in which blood is removed, filtered, and kept, and then returned to the body. Separating platelets, red blood cells, white blood cells, and plasma is possible. A machine is used to withdraw little amounts of blood at a time during the therapy.

The components of blood can be separated in two ways:

Centrifugation spins the blood, dividing it into density-based parts.

Filtration: The plasma is separated from the blood by putting it through a filter. The gadget will reject unhealthy plasma and replace it with healthy plasma from a donor during a plasma exchange. Saline, albumin or a combination of the two can be used to replace hazardous plasma.

In 2030, the Asia Pacific Plasmapheresis Machines Market is predicted to increase at a substantial rate, with a CAGR of 8.95%, reaching a total value of 480 million USD. Individuals with severe multiple myeloma who require supportive care and have renal control failure may benefit from plasmapheresis/plasmapheresis therapy. Increased illness burden, rise in demand for blood components and associated safety, and technological innovation in the creation of innovative apheresis procedures are the primary factors driving the Asia Pacific Plasmapheresis Machines Market.

Market Dynamics

Key Market Drivers

• Modern blood collection facilities, a large presence of blood collection centers, significant product penetration, and high knowledge of blood component donation among the general public are all aspects that contribute to Asia Pacific's success. A growing end-user base, a growing population, and an increase in the prevalence of blood disorders are further driving the Asia Pacific region market.

• Spike in R & D investment: The rising number of platelet donors and biopharmaceutical companies' R&D efforts in Asia Pacific region is projected to have a big impact. Many biotech companies have started investing more and more to produce in order to net new technological breakthroughs for getting better and more advanced products. This factor is a potential driver in increasing the demand for these apheresis machines.

Key Market Restraints

• Histocompatibility: It is the degree of resemblance between two person’s histocompatibility antigens. The ability to tolerate an organ transplant is determined by histocompatibility. Histocompatibility is a very significant factor that can impede market growth as the transplantation process viability is decided by this biological term i.e., Histocompatibility.

• The Expensive Procedure: Plasmapheresis might cost anything from USD 5,000 to USD 10,000 for each session in the Asia-Pacific area. In some circumstances, this treatment will have to be repeated, and it will only be effective if people have medical insurance that covers such high costs. This is an unaffordable alternative for people from low-income households in emerging countries, and this, combined with unfavorable reimbursement constraints, is projected to hinder market growth during the forecast period.

Key Market Opportunities

• Growing awareness of autoimmune diseases and other blood-related conditions: Rising knowledge of autoimmune diseases and other blood-related conditions in emerging countries is expected to have a positive impact on plasmapheresis equipment, resulting in significant future demand for plasmapheresis machines. Nowadays, people are getting more concerned and taking these autoimmune diseases more seriously than ever before, which has enhanced the demand for these machines and the trend is expected to remain the same in the future.

Segmental Analysis

The Asia Pacific Plasmapheresis Machines Market region is divided into four categories: type, application, end-user, and geography.

Multicomponent Collection Systems (MCCS) is a type of improved plasma collection system that collects different components of human blood during donation. It's frequently mixed with plasma as well as other components like serum, RBCs, and leukocytes. Although some definitions define the multi-component collection as a technique that yields two distinct blood components, the vast majority of research papers written by scientists around the world define multicomponent apheresis as a procedure that yields two or more identical or distinct blood components. The same centrifugation processes used for collecting each component individually under diverse circumstances are routinely applied for these multicomponent collections.

Plasmapheresis is an extracorporeal therapy procedure that involves the removal, treatment, return, and exchange of blood plasma and its constituents from and into the circulatory system. An extracorporeal procedure is one that takes place outside of the body. The extracorporeal therapy segment is growing due to an increase in autoimmune disorders such as thrombotic thrombocytopenic purpura, Goodpasture's syndrome, lupus, Guillain-Barre syndrome, myasthenia gravis, and other chronic illnesses, as well as government reimbursement programs in developed countries and rising demand for plasma-derived medicines.

The hospitals and clinics category is expected to obtain the largest market share due to the recent COVID-19 pandemic increase. Due to COVID-19 infection, the frequency of therapeutic plasma exchange surgeries has increased, as have plasma and blood component contributions. During the forecast period, hospitals with in-house transfusion facilities are expected to improve the most.

Regional Analysis

With a CAGR of 8.95 percent, the Asia Pacific Plasmapheresis Machines Market is expected to grow significantly by 2030, reaching a total value of 480 million USD. Plasmapheresis/plasmapheresis therapy may benefit those with severe multiple myeloma who need supportive care and have renal control failure. The Asia Pacific apheresis market is being driven by increased disease burden, increased demand for blood components and associated safety, and technological innovation in the invention of revolutionary apheresis methods.

Asia Pacific is one of the most promising markets for Apheresis market growth, and it is expected to grow at the fastest rate throughout the forecast period. Factors like the rising prevalence of blood illnesses that necessitate plasma and platelet transfusions, rising demography, and burgeoning economies in countries like India and China are expected to propel this region's industry forward.

In India, China, and Japan, favorable reimbursement policies and increased healthcare infrastructure are pushing apheresis equipment sales. Other reasons such as the introduction of advanced versions with automated interface systems, screen navigation, and graphical user interface displays, as well as increasing R&D spending, are expected to drive the market in the coming years.

High awareness and initiatives to improve the healthcare system in Japan are driving the market growth. The medical industry is becoming increasingly important to the country. Apheresis is utilized in the country to treat a variety of disorders. To treat resistant familial hypercholesterolemia, low-density lipoprotein (LDL) apheresis was created (FH). Furthermore, anemia affects nearly 32% of Stage 3-5 chronic renal disease patients. This is because decreased kidney function causes anemia. The elderly population is growing, increasing the burden of chronic diseases. These necessitate the processing of blood. Such elements contribute to Japan's market expansion.

The increased chronic disease burden and the development of innovative products are driving market expansion in South Korea. Plasma exchange was employed in patients with severe fever and SFTS, according to the Korean Journal of Internal Medicine. (Thrombocytopenia syndrome). According to analytical, clinical, and virological standards, the patients' situations improved. As a result, plasma exchange is being studied as a rescue therapy for patients with quickly developing SFTS. In addition, the Ministry of Health and Welfare announced policies to improve management and supervisory responsibilities in blood transfusion services in order to address issues related to a blood supply and demand imbalance. Market expansion in South Korea is fuelled by such reasons.

Recent Developments

• Nigale's plasma separator products were widely used when China started developing convalescent plasma to treat patients infected with COVID-19.

Asia Pacific Plasmapheresis Machines Market Segmentation

By Type

• Plasma Collection System
• Multi-Component Collection System

By Application

• Extracorporeal Therapy
• Plasma Donation

By End-User

• Biopharmaceutical Companies
• Hospitals and Clinics
• Others

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific